Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling

Drug Metabolism and Disposition

Volumn 30, Issue 1, 2002, Pages 86-95

  Wang, Q ^a   Halpert, J R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN; AMFEBUTAMONE; BENZPHETAMINE; BENZYLOXYRESORUFIN; CINNARIZINE; COUMARIN DERIVATIVE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C5; LIDOCAINE; RESORUFIN DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL;

AMINO ACID SEQUENCE; ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; DATA BASE; DEALKYLATION; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; HYDROPHOBICITY; HYDROXYLATION; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REACTION ANALYSIS; THREE DIMENSIONAL IMAGING;

AMINO ACID SEQUENCE; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

EID: 0036135826     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.1.86     Document Type: Article

References (40)

1. Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling and three-dimensional quantitative structure-activity relationship analysis
2. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes
3. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
4. A novel approach to predicting P450-mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
5. Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes
6. Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis
7. The role of cytochrome 2B I substrate recognition site residues 115, 294, 297, 298 and 362 in the oxidation of steroids and 7-alkoxycoumarins
8. Three-and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
9. Three-dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
10. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
11. Three-dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6
12. Three-dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates
13. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites
14. Further characterization of the expression in liver and catalytic activity of CYP2B6
15. Examination of purported probes of human CYP2B6
16. Metabolism of B-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450
17. Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression levels in human liver
18. Catalytic role of cytochrome P250 2B6 in the N-demethylation of S-mephenytoin
19. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P450 2C9
20. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes
21. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: A study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs
22. A predictive model for substrates of cytochrome P450-debrisoquine (2D6)
23. 5 binding site and comparisons with CYP2B1 and CYP2B4
24. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
25. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening
26. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19, and the 3A subfamily
27. A 175-psec molecular dynamics simulation of camphorbound cytochrome P-450cam
28. Predicting the product specificity and coupling of cytochrome P450cam
29. A close family resemblance: The importance of structure in understanding cytochromes P450
30. A refined 3-dimensional QSAR of cytochrome P450 2C9: Computational predictions of drug interactions
31. Human cytochrume P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
32. Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles
33. Human liver CYP2B6-catalyzed hydroxylation of RP73401
34. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies
35. Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450
36. Molecular modeling of cytochrome P450 3A4
37. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity
38. Inter-individual variability in the oxidation of 1,2-dibromoethane: Use of heterologously expressed human cytochrome P450 and human liver microsomes
39. 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes